Combination of
Amlodipine Calcium channel blocker
Valsartan Angiotensin II receptor antagonist
Clinical data
  • US: D (Evidence of risk)
Routes of
ATC code C09DB01 (WHO)
Legal status
Legal status
CAS Number 1190398-97-0
PubChem (CID) 11354874
ChemSpider 13092186 YesY
KEGG D09745 YesY

Amlodipine/valsartan is of an oral blood pressure lowering combination drug which combines two medications in a film-coated tablet. It contains amlodipine, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist (ARB or A2RA); typically formulated as the benzenesulfonate salt. Meta-analysis has shown this combination to be well tolerated and effective for the reduction of blood pressure.[1]

The combination was originally patented by Novartis Pharmaceuticals under the brand name Exforge. The patent expired in September 2012.[2]

Amlodipine/valsartan is available in different dose preparations: 5 mg/80 mg, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10/320 mg of amlodipine and valsartan, respectively.

The combination is also available with included hydrochlorothiazide, for patients who need a three drug regimen to manage their blood pressure.


  1. Eckert, Siegfried; Freytag, Siegfried B.; Müller, Alfons; Klebs, Sven H. G. (2013). "Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors". Blood Pressure. 22 (sup1): 11–21. doi:10.3109/08037051.2013.793891. ISSN 0803-7051.
  2. "Generic Exforge HCT". Retrieved 2012-03-05.

External links

This article is issued from Wikipedia - version of the 11/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.